WebFeb 12, 2013 · Lemmink has nothing to disclose. Tuesday, March 19 2013, 2:00 pm-6:30 pm. OBJECTIVE: Describing clinical and mutational characteristics findings in Dutch SMARD1 patients. BACKGROUND: Since discovery of the IGHMBP2 gene causing spinal muscular atrophy with respiratory distress type 1 (SMARD1) in 2001, over 100 patients … WebSpecialties: Lucky Penny take-away café offers wood-fired pizza, seasonal salads, made-to-order sandwiches, and beer & wine. Enjoy your meal onsite in our picnic area or grab …
Cardio Gene panel experience. Jan Jongbloed Laboratory …
WebHenny H. Lemmink's 10 research works with 78 citations and 1,395 reads, including: The aggressive behaviour of squamous cell carcinoma in epidermolysis bullosa: Analysis of … WebSpinal muscular atrophy (SMA) is one of the leading genetic causes of infant mortality with an incidence of 1:10,000. The recently-introduced antisense oligonucleotide treatment improves the outcome of this disease, in particular when applied at an early stage of progression. The genetic cause of SMA is, in >95% of cases, a homozygous deletion … feed hold button
Henny LEMMINK University of Groningen, Groningen
WebMar 17, 2024 · Kristin M. Abbott,z Henny H. Lemmink,z Minna Toivonen,x Johanna Schleutker,x{Caren Gentile,k Vivianna M. Van Deerlin,k Huiping Zhu,* and Gary J. Latham* From Research and Development, Asuragen Inc.,* Austin, Texas; the GenePhile Bioscience Laboratory,y Ko’s Obstetrics and Gynecology Clinic, Taipei City, WebJul 7, 2024 · “Our laboratory has many years of experience testing various methodologies for the quantification of SMN1 and SMN2, but the [AmplideX SMA Plus Kit] has now set … WebAbstract Spinal muscular atrophy (SMA) is one of the leading genetic causes of infant mortality with an incidence of 1:10,000. The recently-introduced antisense oligonucleotide treatment improves the outcome of this disease, in particular when applied at … feed hold cnc